MOMETASONE 50 MCG
MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE) : 50 MCG · DIN 02551756 · SIVEM PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is MOMETASONE?
MOMETASONE 50 MCG contains MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE) : 50 MCG. It is listed in the Health Canada Drug Product Database under DIN 02551756, held by SIVEM PHARMACEUTICALS ULC, supplied as SPRAY, METERED DOSE for NASAL administration. Health Canada currently lists it as marketed, status dated 06-Jun-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MOMETASONE used for?
Seasonal/perennial allergic rhinitis (ages 3-11); adjunctive treatment for acute rhinosinusitis (12+); mild to moderate acute rhinosinusitis (12+); nasal polyps (18+).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02551756 |
|---|---|
| Brand name | MOMETASONE |
| Generic / active ingredient | MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE) : 50 MCG |
| Manufacturer | SIVEM PHARMACEUTICALS ULC |
| Strength | 50 MCG |
| Dosage form | SPRAY, METERED DOSE |
| Route of administration | NASAL |
| Schedule | Prescription |
| ATC code | R01AD09 MOMETASONE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 06-Jun-2025 |
How is it administered?
Allergic Rhinitis (3-11y): 1 spray/nostril QD. Adjunctive Rhinosinusitis/Polyps (12y+): 2 sprays/nostril BID. Prime pump before use. Shake well. Administer intranasally.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 2ºC and 25ºC. Protect from light. Do not freeze.
How is it supplied?
Supplied in a single pack (1 bottle) delivering 140 metered doses.
Contraindications
Hypersensitivity to any ingredient. Use with caution in patients with active/quiescent tuberculous infections, untreated fungal, bacterial, systemic viral infections, or ocular herpes simplex.
Warnings and precautions
Risk of HPA axis suppression when transferring from systemic steroids. Avoid use in untreated nasal infection or recent nasal surgery/trauma. Monitor for vision changes (cataracts, glaucoma).
What can be used instead?
Other Canadian products sharing ATC code R01AD09 MOMETASONE. 6 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-MOMETASONE | 50 MCG | SPRAY, METERED DOSE | APOTEX INC | MARKETED | DIN 02403587 |
| MOMETASONE | 50 MCG | SPRAY, METERED DOSE | SANIS HEALTH INC | MARKETED | DIN 02519127 |
| NASONEX | 50 MCG | SPRAY, METERED DOSE | ORGANON CANADA INC. | MARKETED | DIN 02238465 |
| SANDOZ MOMETASONE | 50 MCG | SPRAY, METERED DOSE | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02449811 |
| TEVA-MOMETASONE | 50 MCG | SPRAY, METERED DOSE | TEVA CANADA LIMITED | MARKETED | DIN 02475863 |
| MOSASPRAY | 50 MCG | SPRAY, METERED DOSE | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02455870 |
| NASAL ALLERGY AND CONGESTION RELIEF | 50 MCG | SPRAY, METERED DOSE | APOTEX INC | APPROVED | DIN 02451905 |
| NASONEX ALLERGY AND CONGESTION | 50 MCG | SPRAY, METERED DOSE | MERCK CANADA INC | CANCELLED PRE MARKET | DIN 02410524 |
Who else supplies MOMETASONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MOMETASONE appears in 2383 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.